Fractionated stereotactic radiotherapy for acoustic neuromas

J. A. Williams, E. O. Backlund, Henry Brem

Research output: Contribution to journalArticle

Abstract

Background. When compared to radiosurgery, fractionated stereotactic radiotherapy (FSR) for acoustic neuroma (AN) offers escalation of tumor dose (Gy) and potential sparing of auditory and facial nerve functions. Method. Over the past 6.5 years 287 consecutive patients have received FSR for AN. One hundred fifty patients have follow up greater than 1 year and comprise this report. Non-invasive, repeat-fixation mask allowed simulation via spiral CT. Differential collimation and beam weighting achieved conformality. Three distinct schedules for total dose and fractionation were used. For AN <3.0 cm diameter (mean volume 1.5 ± 0.2 cc), ≥3.0 and ≤3.9 cm (mean volume 8.7 ± 1.0 cc) and ≥4.0 cm (mean volume 28.3 cc (one case) doses of 5 Gy given in 5 consecutive daily fractions (25 Gy total) (131 patient), 10 fractions of 3 Gy (30 Gy total) (18 pts), or 20 fractions of 2 Gy (1 patient) were given. All treatments were prescribed to the 80% isodose and given via the dedicated 10 MeV accelerator. Findings. The percentage decreases in tumor size were 14 ± 1 (range: 0-100), 15 ± 3 (range 0-38) and 8 for the 25, 30 and 40 Gy regimens, respectively. No patient had growth of AN or developed facial weakness. Two patients developed transient decrease in facial sensation. Rates of hearing preservation were similar for both the larger and smaller tumors. Interpretation. Fractionated stereotactic radiotherapy may preserve normal function and control both small and large acoustic neuromas.

Original languageEnglish (US)
Pages (from-to)1249-1254
Number of pages6
JournalActa Neurochirurgica
Volume144
Issue number12
DOIs
StatePublished - 2002

Fingerprint

Acoustic Neuroma
Radiotherapy
Dose Fractionation
Neoplasms
Cochlear Nerve
Radiosurgery
Spiral Computed Tomography
Facial Nerve
Masks
Hearing
Appointments and Schedules
Growth

Keywords

  • Acoustic neuroma
  • Fractionation
  • Radiosurgery
  • Radiotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Fractionated stereotactic radiotherapy for acoustic neuromas. / Williams, J. A.; Backlund, E. O.; Brem, Henry.

In: Acta Neurochirurgica, Vol. 144, No. 12, 2002, p. 1249-1254.

Research output: Contribution to journalArticle

Williams, J. A. ; Backlund, E. O. ; Brem, Henry. / Fractionated stereotactic radiotherapy for acoustic neuromas. In: Acta Neurochirurgica. 2002 ; Vol. 144, No. 12. pp. 1249-1254.
@article{7f4bdbe4397749b6af63dd30815e071b,
title = "Fractionated stereotactic radiotherapy for acoustic neuromas",
abstract = "Background. When compared to radiosurgery, fractionated stereotactic radiotherapy (FSR) for acoustic neuroma (AN) offers escalation of tumor dose (Gy) and potential sparing of auditory and facial nerve functions. Method. Over the past 6.5 years 287 consecutive patients have received FSR for AN. One hundred fifty patients have follow up greater than 1 year and comprise this report. Non-invasive, repeat-fixation mask allowed simulation via spiral CT. Differential collimation and beam weighting achieved conformality. Three distinct schedules for total dose and fractionation were used. For AN <3.0 cm diameter (mean volume 1.5 ± 0.2 cc), ≥3.0 and ≤3.9 cm (mean volume 8.7 ± 1.0 cc) and ≥4.0 cm (mean volume 28.3 cc (one case) doses of 5 Gy given in 5 consecutive daily fractions (25 Gy total) (131 patient), 10 fractions of 3 Gy (30 Gy total) (18 pts), or 20 fractions of 2 Gy (1 patient) were given. All treatments were prescribed to the 80{\%} isodose and given via the dedicated 10 MeV accelerator. Findings. The percentage decreases in tumor size were 14 ± 1 (range: 0-100), 15 ± 3 (range 0-38) and 8 for the 25, 30 and 40 Gy regimens, respectively. No patient had growth of AN or developed facial weakness. Two patients developed transient decrease in facial sensation. Rates of hearing preservation were similar for both the larger and smaller tumors. Interpretation. Fractionated stereotactic radiotherapy may preserve normal function and control both small and large acoustic neuromas.",
keywords = "Acoustic neuroma, Fractionation, Radiosurgery, Radiotherapy",
author = "Williams, {J. A.} and Backlund, {E. O.} and Henry Brem",
year = "2002",
doi = "10.1007/s00701-002-0974-x",
language = "English (US)",
volume = "144",
pages = "1249--1254",
journal = "Acta Neurochirurgica",
issn = "0001-6268",
publisher = "Springer Wien",
number = "12",

}

TY - JOUR

T1 - Fractionated stereotactic radiotherapy for acoustic neuromas

AU - Williams, J. A.

AU - Backlund, E. O.

AU - Brem, Henry

PY - 2002

Y1 - 2002

N2 - Background. When compared to radiosurgery, fractionated stereotactic radiotherapy (FSR) for acoustic neuroma (AN) offers escalation of tumor dose (Gy) and potential sparing of auditory and facial nerve functions. Method. Over the past 6.5 years 287 consecutive patients have received FSR for AN. One hundred fifty patients have follow up greater than 1 year and comprise this report. Non-invasive, repeat-fixation mask allowed simulation via spiral CT. Differential collimation and beam weighting achieved conformality. Three distinct schedules for total dose and fractionation were used. For AN <3.0 cm diameter (mean volume 1.5 ± 0.2 cc), ≥3.0 and ≤3.9 cm (mean volume 8.7 ± 1.0 cc) and ≥4.0 cm (mean volume 28.3 cc (one case) doses of 5 Gy given in 5 consecutive daily fractions (25 Gy total) (131 patient), 10 fractions of 3 Gy (30 Gy total) (18 pts), or 20 fractions of 2 Gy (1 patient) were given. All treatments were prescribed to the 80% isodose and given via the dedicated 10 MeV accelerator. Findings. The percentage decreases in tumor size were 14 ± 1 (range: 0-100), 15 ± 3 (range 0-38) and 8 for the 25, 30 and 40 Gy regimens, respectively. No patient had growth of AN or developed facial weakness. Two patients developed transient decrease in facial sensation. Rates of hearing preservation were similar for both the larger and smaller tumors. Interpretation. Fractionated stereotactic radiotherapy may preserve normal function and control both small and large acoustic neuromas.

AB - Background. When compared to radiosurgery, fractionated stereotactic radiotherapy (FSR) for acoustic neuroma (AN) offers escalation of tumor dose (Gy) and potential sparing of auditory and facial nerve functions. Method. Over the past 6.5 years 287 consecutive patients have received FSR for AN. One hundred fifty patients have follow up greater than 1 year and comprise this report. Non-invasive, repeat-fixation mask allowed simulation via spiral CT. Differential collimation and beam weighting achieved conformality. Three distinct schedules for total dose and fractionation were used. For AN <3.0 cm diameter (mean volume 1.5 ± 0.2 cc), ≥3.0 and ≤3.9 cm (mean volume 8.7 ± 1.0 cc) and ≥4.0 cm (mean volume 28.3 cc (one case) doses of 5 Gy given in 5 consecutive daily fractions (25 Gy total) (131 patient), 10 fractions of 3 Gy (30 Gy total) (18 pts), or 20 fractions of 2 Gy (1 patient) were given. All treatments were prescribed to the 80% isodose and given via the dedicated 10 MeV accelerator. Findings. The percentage decreases in tumor size were 14 ± 1 (range: 0-100), 15 ± 3 (range 0-38) and 8 for the 25, 30 and 40 Gy regimens, respectively. No patient had growth of AN or developed facial weakness. Two patients developed transient decrease in facial sensation. Rates of hearing preservation were similar for both the larger and smaller tumors. Interpretation. Fractionated stereotactic radiotherapy may preserve normal function and control both small and large acoustic neuromas.

KW - Acoustic neuroma

KW - Fractionation

KW - Radiosurgery

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0036460610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036460610&partnerID=8YFLogxK

U2 - 10.1007/s00701-002-0974-x

DO - 10.1007/s00701-002-0974-x

M3 - Article

C2 - 12478335

AN - SCOPUS:0036460610

VL - 144

SP - 1249

EP - 1254

JO - Acta Neurochirurgica

JF - Acta Neurochirurgica

SN - 0001-6268

IS - 12

ER -